Stakeholders’ experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands
As the Drug Access Protocol may be a promising solution to mitigate uncertainties for healthcare decision-makers, implementation challenges can hamper its feasibility. Addressing these challenges could realise the potential of such programmes.
Authors
- Atse H Huisman (ORCID: https://orcid.org/0000-0003-4122-5348)
- Haiko J. Bloemendal (ORCID: https://orcid.org/0000-0002-8902-4337)
- Christine Leopold (ORCID: https://orcid.org/0000-0002-2046-8490)
- Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
- Kevin J. G. M. Vlaar
Institutions
- Radboud University Nijmegen (NL)
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- Radboud University Medical Center (NL)
- Pharmo Institute (NL)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2026-01-14
- DOI
- https://doi.org/10.2340/1651-226x.2026.45000
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 99.81
Funders
- HORIZON EUROPE Framework Programme